Gastric Cancer
Advertisement
Grace-Ann Fasaye discusses the elevated lifetime risk of gastric cancer in patients with CDH1 gene variants.
Researchers reported that a buildup of lactate was most notable in chemotherapy-resistant cancer tissues.
Drs. Uboha and Karasic discuss the benefits and considerations of treating gastric cancer with an anti-CCR8 antibody.
The study’s primary endpoint was the connection between OS and post-recurrence survival.
Drs. David H. Ilson and Nataliya Uboha highlight the final OS results of the phase 3 SPOTLIGHT study.
Claudin 18 isoform 2 is an emerging therapeutic target in gastric and gastroesophageal cancers.
Phase 3 IKF-575/RENAISSANCE trial shows surgery after FLOT may benefit RPLN-only metastatic gastric cancer patients.
Switch maintenance may extend the benefits of an initial treatment strategy and can delay clinical deterioration.
Drs. Filippo Pietrantonio and Nataliya Uboha break down the results of the phase 3 ARMANI trial.
The primary end point of the analysis was OS, and secondary end points included PFS and ORR.
Patients with mPR experienced improved PFS and OS with pembrolizumab plus chemotherapy over placebo plus chemotherapy.
RELATIVITY-060 investigated the efficacy of first-line relatlimab and nivolumab with chemotherapy for gastric or GEJ cancers.
Drs. Wainberg and Uboha discuss updated results from the FIGHT trial, noting improved OS in gastric cancer/GEJ cancer.
Drs. Brian Badgwell and Nataliya Uboha discuss HIPEC for managing gastric cancer, highlighting its use with cytoreduction.
Bemarituzumab is a humanized monoclonal antibody that is selective for FGFR2b.
Dr. Sethi continues his comments on NER deficiency in gastric cancer cell lines in response to cisplatin treatment.
Dr. Sethi discusses homologous recombination and nucleotide excision repair pathways in DNA repair for cancers.
Dr. Rodón Ahnert compares the differences of sacituzumab tirumotecan use in the second- vs third-line setting for patients.
Pembrolizumab Shows Promise as a First-line Treatment for Advanced Gastric, Gastroesophageal Cancers
The final results from the KEYNOTE-811 trial will determine if Keytruda will receive continued approval from the FDA.HERCESSI was developed by Accord BioPharma, Inc., the US specialty division of Intas Pharmaceuticals Ltd.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.